The past few days have been hard on many traders. We are all looking at a sea of red in our portfolios. This happens when you invest. Markets go up. Markets go down.
What’s An Investor To Do?
First, it’s important to understand the 3 most important rules of investing.
- Buy low.
- Sell high.
- Don’t be afraid to take profits.
It has been an incredible run for OTC stock investors so far in 2021. We all have made a tremendous amount of money. Investors should have been periodically selling and booking gains.
If an investor has not been selling along the way, they got greedy. Plain and simple.
With social media, it’s easier now than ever to determine market sentiment. The bullish sentiment just got too extreme. Valuations got too far out of whack. For those that say valuation doesn’t matter, it does.
Plan To Action
There are two choices for investors right now because selling is not an option.
One, investors can do their homework and look for OTC stocks that haven’t run yet. This is what we do at Insider Financial. We scan through hundreds of OTC stocks each week looking for the best alerts for our subscribers.
We preach the key to trading OTC stocks is finding momentum BEFORE it happens and then be patient. Now, when we say that we find momentum BEFORE it happens, we are investors looking to position our subscribers BEFORE the move happens.
We got our subscribers in early on TSNP, which you can read our first article here, and ALPP, which you can read about here. This is where the big money is made and why so many of our subscribers are sitting on gains of over 9633% in ALPP and over 19,900% in TSNP.
It’s also best to own a portfolio of quality OTC stocks. For some that can be as many as 10 to 20 or more OTC stocks.
We always alert our subscribers first before we publish for our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here. We alert our subscribers with our best ideas before our regular readers.
The second move for OTC stock investors is to look for quality OTC stocks that you might have missed the earlier move on and buy the dip. When we say quality, we are looking for OTC QBs.
What Is An OTC QB?
These companies must be current in their financial reporting, undergo an annual verification and management certification process, and have a bid price of at least $0.01. They also cannot be in bankruptcy. Over 900 companies trade on the OTCQB Market.
In this article, we take a look at 4 OTC stock dip buys, American Battery Metals (OTCMKTS: ABML), Alpine 4 Technologies (OTCMKTS: ALPP), CytoDyn (OTCMKTS: CYDY), and Northwest Biotherapeutics (OTCMKTS: NWBO).
OTC Stock Dip Buys ABML
ABML has been a big winner for Insider Financial subscribers. We recommended ABML last year when the stock was trading at just $.06 a share, which you can read here. This is what we mean when we say find the momentum BEFORE it happens!!
ABML is a smart play on the electric vehicle (EV) boom with its pilot lithium-ion battery recycling plant in Fernley, Nevada. Elon Musk has said repeatedly that his biggest obstacle is ensuring that Tesla has enough raw materials to meet the demand for the lithium-ion batteries it needs.
Over the past three months, ABML has achieved four critical milestones that enable the Company to move ahead in permitting, constructing, and commissioning its pilot lithium-ion battery recycling plant in Fernley, Nevada:
- Purchased the Pilot Factory Land – ABML purchased 12.44 acres of undeveloped land located at 345 Winston Lane, Fernley, Lyon County, Nevada. ABML will be constructing five separate building areas on this property to create a Pilot Plant campus that includes: Production Process Areas, Feedstock Sorting Area, Analytical Laboratory Spaces & Process Development Bays, a Storage Warehouse, and general Office Space.
- Secured Water Rights – ABML has secured multiple water allocations from the Fernley Area Basin 76 (Lyon, Washoe, Storey, and Churchill Counties) of Nevada’s West Central Region (Hydrographic Region 5). By securing these water rights, ABML ensures it can operate its pilot facility at full throughput with adequate water capacity for many years to come.
- Hired Design/Build Construction Firm – ABML has selected Miles Construction as the design-build contractor for its Fernley pilot plant campus. ABML is finalizing its permitting processes with the City and NDEP and will announce updated permitting and construction timelines in early 2021.
Furthermore, former Tesla executive Ryan Melsert and his team at ABML have been awarded $4.5 million in gov funding for field demonstration of selective leaching, targeted purification, and electrochemical production of battery-grade lithium hydroxide precursor from domestic claystone resources.
OTC Stock Dip Buys ALPP
ALPP has been another big winner for Insider Financial subscribers since we started covering the company at just $.075 a share, which you can read here. As you can see from the chart below, ALPP keeps making higher lows and higher highs.
ALPP is running as the company prepares to uplist to the NASDAQ. OTC to NASDAQ plays are some of the best plays in the market as once the company hits the NASDAQ, institutions can more easily purchase shares.
ALPP is also cleaning up its balance sheet in preparation for this uplisting. ALPP just retired $12.8 million in both short and long-term debt in its first-round debt payoffs.
Kent Wilson, CEO of Alpine 4, had this to say, “From the beginning, we built the company on a Leverage Buy-Out model. We did this to maintain the integrity of our equity and avoid having a multibillion share, share structure. I always knew that our PPS would grow to a point where our cost of equity would become attractive and allow us to transition away from debt. Our reduction of this debt will give Alpine 4 and our subsidiaries a unique competitive advantage by allowing for; better-purchasing practices, reducing our overhead burden, and ultimately leading to enhanced profitability. Subsequently, this competitive advantage will also drive larger revenue and profit back to our subsidiaries, strengthening our balance sheet allowing the company to invest in value-added opportunities. Needless to say, we are very excited at Alpine 4 on what this payoff means for us as a company and look forward to the fruits it will bear.”
Here are a few reasons why ALPP is a buy-the-dip OTC stock.
- ALPP now has over 24,000 shareholders throughout Europe and a growing number of shareholders in Asia and beyond.
- ALPP forecasts $42 million to $55 million in revenues this year.
- NASDAQ bound
- ALPP is looking at acquisitions that can add $25 million to $40 million in annual revenue.
- A bet on ALPP is also a bet on founder and CEO Kent Wilson. He is an expert on DMAIC / Six Sigma and Lean proficiencies. These are the strategies Jack Welch used to build GE.
OTC Stock Dip Buys CYDY
My colleague Chris Sandburg has covered CYDY better than anyone. You can read his full coverage here.
Chris is out with a new article today where he says that the latest Leronlimab trial results point to near-certain approval for CytoDyn. He says:
Investors should be betting on approval, and not Adam Feuerstein’s foul analysis. A stock price of $4.00 is factoring in failure and creates one heck of a buying opportunity for the longs that only have to wait 2 – 3 weeks to prove their investment thesis that the stock is worth many multiples of the current price.
Need we say more?
CYDY is a buy-the-dip opportunity if there ever was one on the OTC Markets.
OTC Stock Dip Buys NWBO
NWBO is a lotto ticket waiting on news to hit the tape. We said back in September that NWBO has enormous potential and we remain bullish.
We are all waiting for the company to UNBLIND, UNVEIL, and ANNOUNCE, **finally,** the results of its THIRTEEN YEAR LONG PHASE THREE TRIAL OF DCVAX FOR GLIOBLASTOMA BRAIN CANCER.
Top-line data is imminent. The database for the Phase 3 trial of DCVax-L for Glioblastoma has been locked, which means that only the firms managing the trial have access to the data for analyses and to prepare summaries of the trial results.
The recent data is that brain and other nervous system cancers are the 10th leading cause of death for men and women. Globally, over 241,000 people die each year as a result of brain or nervous system cancer, with GBM being the most common form of the disease. GBM has an incidence of two to three per 100,000 adults per year and accounts for 52 percent of all primary brain tumors.
Glioblastoma is the most common primary malignant form of brain cancer. Despite technological advances in surgery and radio-chemotherapy, glioblastoma remains largely resistant to treatment. The standard treatment for glioblastoma is surgery. The choice of drug therapy for glioblastoma is still limited to a handful of compounds.
An effective treatment is needed and that treatment is DCVax-L. The past 13 years have been a long road, but the payoff is just around the corner for Northwest Bio and its shareholders.
These 4 OTC stocks are worthwhile dip buys. There are always opportunities in the markets and it’s our job to find winning stocks. Huge gains can be made in such a short amount of time.
Our best advice is to be patient and throw bids in below the market. Buying dips and selling rips as swing trades remains the best strategy in these markets.
Remember, all it takes is one or two to become a winner and you’ve crushed the market indices for the year.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.